Plasma exchange in neuroimmunological disorders: Part 1: Rationale and treatment of inflammatory central nervous system disorders

Archives of Neurology

Volumn 63, Issue 7, 2006, Pages 930-935

  Lehmann, Helmar C ^a   Hartung, Hans Peter ^a   Hetzel, Gerd R ^a   Stüve, Olaf ^b   Kieseier, Bernd C ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; AUTOANTIBODY; AZATHIOPRINE; CITRIC ACID; CORTICOSTEROID; CYTOKINE; FRESH FROZEN PLASMA;

BLEEDING; DEMYELINATING DISEASE; EATON LAMBERT SYNDROME; GUILLAIN BARRE SYNDROME; HUMAN; HYPOCALCEMIA; INFECTION; MULTIPLE SCLEROSIS; MYASTHENIA GRAVIS; NEUROIMMUNOLOGY; NEUROLOGIC DISEASE; PARANEOPLASTIC SYNDROME; PLASMAPHERESIS; PNEUMOTHORAX; PRIORITY JOURNAL; RASMUSSEN SYNDROME; REVIEW; SEPTICEMIA; THROMBOSIS;

CENTRAL NERVOUS SYSTEM DISEASES; HUMANS; NEUROIMMUNOMODULATION; PLASMA EXCHANGE;

EID: 33745809518     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneur.63.7.930     Document Type: Review

References (57)

1. Clark WF, Rock GA, Buskard N, et al. Therapeutic plasma exchange: an update from the Canadian Apheresis Group. Ann Intern Med. 1999;131:453-462.
2. Weinstein R. Therapeutic apheresis in neurological disorders. J Clin Apheresis. 2000;15:74-128.
3. Goodin DS, Frohman EM, Garmany GP Jr, et al; Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines [published correction appears in Neurology. 2002;59:480]. Neurology. 2002;58:169-178.
4. Edlund W, Gronseth G, So Y, Franklin G. American Academy of Neurology Clinical Practice Guideline Process Manual: 2004 Edition. http://www.aan.com. Accessed October 7, 2005.
5. Drachman DB. Myasthenia gravis. N Engl J Med. 1994;330:1797-1810.
6. Lennon VA, Kryzer TJ, Griesmann GE, et al. Calcium-channel antibodies in the Lambert-Eaton syndrome and other paraneoplastic syndromes. N Engl J Med. 1995;332:1467-1474.
7. Berger T, Rubner P, Schautzer F, et al. Antimyelin antibodies as a predictor of clinical definite multiple sclerosis after a first demyelinating event. N Engl J Med. 2003;349:139-145.
8. Hartung HP, Archelos JJ, Zielasek J, et al. Circulating adhesion molecules and inflammatory mediators in demyelination: a review. Neurology. 1995;45(suppl 6):S22-S32.
9. Reeves JH, Butt WW, Shann F, et al; Plasmafiltration in Sepsis Study Group. Continuous plasmafiltration in sepsis syndrome. Crit Care Med. 1999;27:2096-2104.
10. Kaplan AA. A Practical Guide to Therapeutic Plasma Exchange. Malden, Mass: Blackwell Sciences; 1999.
11. Wallace DJ, Goldfinger D, Pepkowitz SH, et al. Randomized controlled trial of pulse/synchronization cyclophosphamide/apheresis for proliferative lupus nephritis. J Clin Apheresis. 1998;13:163-166.
12. Dau PC. Increased proliferation of blood mononuclear cells after plasmapheresis treatment of patients with demyelinating disease. J Neuroimmunol. 1990;30:15-21.
13. Dau PC. Increased antibody production in peripheral blood mononuclear cells after plasma exchange therapy in multiple sclerosis. J Neuroimmunol. 1995;62:197-200.
14. De Luca G, Lugaresi A, Iarlori C, et al. Prednisone and plasma exchange improve suppressor cell function in chronic inflammatory demyelinating polyneuropathy. J Neuroimmunol. 1999;95:190-194.
15. Goto H, Matsuo H, Nakane S, et al. Plasmapheresis affects T helper type-1/T helper type-2 balance of circulating peripheral lymphocytes. Ther Apher. 2001;5:494-496.
16. Kambara C, Matsuo H, Fukudome T, Goto H, Shibuya N. Miller Fisher syndrome and plasmapheresis. Ther Apher. 2002;6:450-453.
17. Shariatmadar S, Nassiri M, Vincek V. Effect of plasma exchange on cytokines measured by multianalyte bead array in thrombotic thrombocytopenic purpura. Am J Hematol. 2005;79:83-88.
18. Kaplan AA, Halley SE. Plasma exchange with a rotating filter. Kidney Int. 1990;38:160-166.
19. Korach JM, Berger P, Giraud C, Le Perff-Desman C, Chillet P; French Registry Cooperative Group. Role of replacement fluids in the immediate complications of plasma exchange. Intensive Care Med. 1998;24:452-458.
20. Hershko AY, Naparstek Y. Removal of pathogenic autoantibodies by immunoadsorption. Ann N Y Acad Sci. 2005;1051:635-646.
21. Moldenhauer A, Haas J, Wascher C, et al. Immunoadsorption patients with multiple sclerosis: an open-label pilot study. Eur J Clin Invest. 2005;35:523-530.
22. Yeh JH, Chiu HC. Comparison between double-filtration plasmapheresis and immunoadsorption plasmapheresis in the treatment of patients with myasthenia gravis. J Neurol. 2000;247:510-513.
23. Couriel D, Weinstein R. Complications of therapeutic plasma exchange: a recent assessment. J Clin Apheresis. 1994;9:1-5.
24. Mokrzycki MH, Kaplan AA. Therapeutic plasma exchange: complications and management. Am J Kidney Dis. 1994;23:817-827.
25. Rodnitzky RL, Goeken JA. Complications of plasma exchange in neurological patients. Arch Neurol. 1982;39:350-354.
26. Bouget J, Chevret S, Chastang C, Raphael JC; French Cooperative Group. Plasma exchange morbidity in Guillain-Barré syndrome: results from the French prospective, randomized, multicenter study. Crit Care Med. 1993;21:651-658.
27. Yeh JH, Chen WH, Chiu HC. Complications of double-filtration plasmapheresis. Transfusion. 2004;44:1621-1625.
28. Boucher CA, de Gans J, van Oers R, Danner S, Goudsmit J. Transmission of HIV and AIDS by plasmapheresis for Guillain-Barré syndrome. Clin Neurol Neurosurg. 1988;90:235-236.
29. Hemmer B, Archelos JJ, Hartung HP. New concepts in the immunopathogenesis of multiple sclerosis. Nat Rev Neurosci. 2002;3:291-301.
30. Noseworthy JH, Hartung HP. Multiple sclerosis and related conditions. In: Noseworthy JH, ed. Neurological Therapeutics and Practice. London, England: Martin Dunitz; 2003:1107-1134.
31. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple sclerosis. N Engl J Med. 2000;343:938-952.
32. Archelos JJ, Storch MK, Hartung HP. The role of B cells and autoantibodies in multiple sclerosis. Ann Neurol. 2000;47:694-706.
33. Antel JP, Bar-Or A. Do myelin-directed antibodies predict multiple sclerosis? N Engl J Med. 2003;349:107-109.
34. Khatri BO, McQuillen MP, Harrington GJ, Schmoll D, Hoffmann RG. Chronic progressive multiple sclerosis: double-blind controlled study of plasmapheresis in patients taking immunosuppressive drugs. Neurology. 1985;35:312-319.
35. Canadian Cooperative Multiple Sclerosis Study Group. The Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis. Lancet. 1991;337:441-446.
36. Sorensen PS, Wanscher B, Szpirt W, et al. Plasma exchange combined with azathioprine in multiple sclerosis using serial gadolinium-enhanced MRI to monitor disease activity: a randomized single-masked cross-over pilot study. Neurology. 1996;46:1620-1625.
37. Weiner HL, Dau PC, Khatri BO, et al. Double-blind study of true vs. sham plasma exchange in patients treated with immunosuppression for acute attacks of multiple sclerosis. Neurology. 1989;39:1143-1149.
38. Weinshenker BG, O'Brien PC, Petterson TM, et al. A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol. 1999;46:878-886.
39. Keegan M, Konig F, McClelland R, et al. Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange. Lancet. 2005;366:579-582.
40. Lucchinetti C, Bruck W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol. 2000;47:707-717.
41. Bennetto L, Thotham A, Healy P, Massey E, Scolding N. Plasma exchange in episodes of severe inflammatory demyelination of the central nervous system. J Neurol. 2004;251:1515-1521.
42. Ruprecht K, Klinker E, Dintelmann T, Rieckmann P, Gold R. Plasma exchange for severe optic neuritis: treatment of 10 patients. Neurology. 2004;63:1081-1083.
43. Bien CG, Elger CE, Wiendl H. Advances in pathogenic concepts and therapeutic agents in Rasmussen's encephalitis. Expert Opin Investig Drugs. 2002;11:981-989.
44. Andrews PI, Dichter MA, Berkovic SF, Newton MR, McNamara JO. Plasmapheresis in Rasmussen's encephalitis. Neurology. 1996;46:242-246.
45. Wiendl H, Bien CG, Bernasconi P, et al. GluR3 antibodies: prevalence in focal epilepsy but no specificity for Rasmussen's encephalitis. Neurology. 2001;57:1511-1514.
46. Bernasconi P, Cipilletti B, Passerini L, et al. Similar binding to glutamate receptors by Rasmussen and partial epilepsy patients' sera. Neurology. 2002;59:1998-2001.
47. Bien CG, Granata T, Antozzi C, et al. Pathogenesis, diagnosis and treatment of Rasmussen encephalitis: a European consensus statement. Brain. 2005;128:454-471.
48. Andrews PI, McNamara JO, Lewis DV. Clinical and electroencephalographic correlates in Rasmussen's encephalitis. Epilepsia. 1997;38:189-194.
49. Darnell RB, Posner JB. Paraneoplastic syndromes involving the nervous system. N Engl J Med. 2003;349:1543-1554.
50. Sutton I. Paraneoplastic neurological syndromes. Curr Opin Neurol. 2002;15:685-690.
51. Dalmau J, Graus F, Rosenblum MK, Posner JB. Anti-Hu-associated paraneoplastic encephalomyelitis/sensory neuronopathy: a clinical study of 71 patients. Medicine (Baltimore). 1992;71:59-72.
52. Graus F, Abos J, Roquer J, Mazzara R, Pereira A. Effect of plasmapheresis on serum and CSF autoantibody levels in CNS paraneoplastic syndromes. Neurology. 1990;40:1621-1623.
53. Graus F, Vega F, Delattre JY, et al. Plasmapheresis and antineoplastic treatment in CNS paraneoplastic syndromes with antineuronal autoantibodies. Neurology. 1992;42:536-540.
54. Vicari AM, Folli F, Pozza G, et al. Plasmapheresis in the treatment of stiff-man syndrome [letter]. N Engl J Med. 1989;320:1499.
55. Hayashi A, Nakamagoe K, Ohkoshi N, Hoshino S, Shoji S. Double filtration plasma exchange and immunoadsorption therapy in a case of stiff-man syndrome with negative anti-GAD antibody. J Med. 1999;30:321-327.
56. Hao W, Davis C, Hirsch IB, et al. Plasmapheresis and immunosuppression in stiffman syndrome with type 1 diabetes: a 2-year study. J Neurol. 1999;246:731-735.
57. Coles A, Barker R. A case of stiff limb syndrome responsive to plasma exchange. J Neurol Neurosurg Psychiatry. 2001;70:407-408.